Karianne Schuurman

Karianne Schuurman

Auto-generated profile, based on publicly available information

Karianne Schuurman

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SLSimon Linder
Simon Linder
MHMarlous Hoogstraat
Marlous Hoogstraat
SSSuzan Stelloo
Suzan Stelloo
NENils Eickhoff
Nils Eickhoff
KSKarianne Schuurman
Karianne Schuurman
WZWilbert Zwart
Wilbert Zwart
In prostate cancer, androgen receptor (AR)–targeting agents are very effective in various disease stages. However, therapy resistance inevitably occurs, and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a neuroendocrine-like disease state. Additionally, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 from inactive chromatin sites toward active cis-regulatory elements that dictate prosurvival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian clock component ARNTL. Posttreatment ARNTL levels were associated with patients’ clinical outcomes, and ARNTL knockout strongly decreased prostate cancer cell growth. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy and revealed an acquired dependency on the circadian regulator ARNTL, a novel candidate therapeutic target. Significance: Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel lead for therapeutic development. See related commentary by Zhang et al., p. 2017. This article is highlighted in the In This Issue feature, p. 2007

6 September 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
DKDinja T. Kruger
Dinja T. Kruger
XAXanthippi Alexi
Xanthippi Alexi
MOMark Opdam
Mark Opdam
KSKarianne Schuurman
Karianne Schuurman
LVLeonie Voorwerk
Leonie Voorwerk
SLSabine C. Linn
Sabine C. Linn
Preclinical studies indicate that activated IGF‐1R can drive endocrine resistance in ER‐positive (ER+) breast cancer, but its clinical relevance is unknown. We studied the effect of IGF‐1R signaling on tamoxifen benefit in patients and we searched for approaches to overcome IGF‐1R‐mediated tamoxifen failure in cell lines. Primary tumor blocks from postmenopausal ER+ breast cancer patients randomized between adjuvant tamoxifen versus nil were recollected. Immunohistochemistry for IGF‐1R, p‐IGF‐1R/InsR, p‐ERα(Ser118), p‐ERα(Ser167) and PI3K/MAPK pathway proteins was performed. Multivariate Cox models were employed to assess tamoxifen efficacy. The association between p‐IGF‐1R/InsR and PI3K/MAPK pathway activation in MCF‐7 and T47D cells was analyzed with Western blots. Cell proliferation experiments were performed under various growth‐stimulating and ‐inhibiting conditions. Patients with ER+, IGF‐1R‐positive breast cancer without p‐IGF‐1R/InsR staining (n = 242) had tamoxifen benefit (HR 0.41, p = 0.0038), while the results for p‐IGF‐1R/InsR‐positive patients (n = 125) were not significant (HR 0.95, p = 0.3). High p‐ERα(Ser118) or p‐ERα(Ser167) expression was associated with less tamoxifen benefit. In MCF‐7 cells, IGF‐1R stimulation increased phosphorylation of PI3K/MAPK proteins and ERα(Ser167) regardless of IGF‐1R overexpression. This could be abrogated by the dual IGF‐1R/InsR inhibitor linsitinib, but not by the IGF‐IR‐selective antibody 1H7. In MCF‐7 and T47D cells, stimulation of the IGF‐1R/InsR pathway resulted in cell proliferation regardless of tamoxifen. Abrogation of cell growth was regained by addition of linsitinib. In conclusion, p‐IGF‐1R/InsR positivity in ER+ breast cancer is associated with reduced benefit from adjuvant tamoxifen in postmenopausal patients. In cell lines, stimulation rather than overexpression of IGF‐1R is driving tamoxifen resistance to be abrogated by linsitinib.

30 October 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
Stefan PrekovicStefan Prekovic
Stefan Prekovic
TCTheofilos Chalkiadakis
Theofilos Chalkiadakis
MRMerel Roest
Merel Roest
DRDaniel Roden
Daniel Roden
CLCatrin Lutz
Catrin Lutz
WZWilbert Zwart
Wilbert Zwart
Glucocorticoid receptor (GR) is a transcription factor that plays a crucial role in cancer biology. In this study, we utilized an in silico ‐designed GR activity signature to demonstrate that GR relates to the proliferative capacity of numerous primary cancer types. In breast cancer, the GR activity status determines luminal subtype identity and has implications for patient outcomes. We reveal that GR engages with estrogen receptor (ER), leading to redistribution of ER on the chromatin. Notably, GR activation leads to upregulation of the ZBTB16 gene, encoding for a transcriptional repressor, which controls growth in ER‐positive breast cancer and associates with prognosis in luminal A patients. In relation to ZBTB16 's repressive nature, GR activation leads to epigenetic remodeling and loss of histone acetylation at sites proximal to cancer‐driving genes. Based on these findings, epigenetic inhibitors reduce viability of ER‐positive breast cancer cells that display absence of GR activity. Our findings provide insights into how GR controls ER‐positive breast cancer growth and may have implications for patients' prognostication and provide novel therapeutic candidates for breast cancer treatment.

4 April 2023
Verified
Other
Open access
SLSimon Linder
Simon Linder
MHMarlous Hoogstraat
Marlous Hoogstraat
SSSuzan Stelloo
Suzan Stelloo
NENils Eickhoff
Nils Eickhoff
KSKarianne Schuurman
Karianne Schuurman
WZWilbert Zwart
Wilbert Zwart
In prostate cancer, androgen receptor (AR)–targeting agents are very effective in various disease stages. However, therapy resistance inevitably occurs, and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a neuroendocrine-like disease state. Additionally, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 from inactive chromatin sites toward active cis-regulatory elements that dictate prosurvival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian clock component ARNTL. Posttreatment ARNTL levels were associated with patients’ clinical outcomes, and ARNTL knockout strongly decreased prostate cancer cell growth. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy and revealed an acquired dependency on the circadian regulator ARNTL, a novel candidate therapeutic target.Significance:Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel lead for therapeutic development.See related commentary by Zhang et al., p. 2017.This article is highlighted in the In This Issue feature, p. 2007

10 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ZDZhanna Dauyey
Zhanna Dauyey
AVArno Velds
Arno Velds
RGRoán Gobits
Roán Gobits
IRIris de Rink
Iris de Rink
KSKarianne Schuurman
Karianne Schuurman
WZWilbert Zwart
Wilbert Zwart
Metastatic breast cancer represents a major societal burden and is a main cause of cancer-related death in women, with limited rationale-based treatment options and often dismal outcomes. Intra-tumor heterogeneity, tumor-stromal interactions and clonal selection are considered to play a major role in metastasis formation and disease progression, but these processes remain incompletely understood. Leveraging spatial transcriptomics as cost-effective method for generating transcriptomics data at single-cell resolution, we present a single-cell spatial transcriptomics atlas of 126 tumor samples from 44 metastatic breast cancer patients, encompassing 520,850 cells from primary and metastatic lesions, with 171,766 cancer cells and 349,084 cells belonging to the tumor microenvironment. For most patients, multiple time-points of sample collection throughout metastatic disease progression were analyzed, allowing for detection of treatment-induced transcriptional changes driving therapy resistance within the tumor cell compartment. Distinct immune cell subpopulations were enriched upon progression following specific therapeutics and were predictive for hormone receptor loss. By inferring DNA copy number alterations from the single-cell transcriptomics data, we tracked subclonal tumor cell selection upon progression and identified critical transcriptomic features of outcompeting clones with future metastatic potential. Cumulatively, we present a unique single-cell spatial framework on metastatic breast cancer development and progression, in a highly complex systemic treatment landscape.

4 April 2023
Verified
Other
Open access
SLSimon Linder
Simon Linder
MHMarlous Hoogstraat
Marlous Hoogstraat
SSSuzan Stelloo
Suzan Stelloo
NENils Eickhoff
Nils Eickhoff
KSKarianne Schuurman
Karianne Schuurman
WZWilbert Zwart
Wilbert Zwart
Supplementary Data from Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence